Karen Autio

16PUBLICATIONS
210CO-AUTHORS
Predictive and prognostic markersMolecular targetsRadiation therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Toxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 18, 2026
Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer.

Jeffery C W Chang, Subhiksha Nandakumar, Konrad H Stopsack

|Nov 20, 2025
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.

Deaglan McHugh, Matthew Dallos, Min Yuen Teo

|Oct 23, 2025
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.

David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching

|Sep 04, 2025
A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes.

Karen A Autio, Christos E Kyriakopoulos, Paul Palyca

|Jun 01, 2025
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Mark N Stein, Armelle Vinceneux, Debbie Robbrecht

|Apr 24, 2025
Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer.

Karen A Autio, Deaglan J McHugh, Dana E Rathkopf

Pageof 3

Frequent Collaborators

4 joint publications

Dana Rathkopf

3 joint publications

Konrad H Stopsack

3 joint publications

Howard I Scher

2 joint publications

Joel Nowak